VYNE Therapeutics Sees 27.6% Drop in Short Interest in January

VYNE Therapeutics Inc. (NASDAQ:VYNE) experienced a notable decrease in short interest during January 2024. As of January 30, short interest totaled 544,777 shares, reflecting a reduction of 27.6% from the previous total of 752,574 shares reported on January 15. Currently, about 1.7% of the company’s shares are sold short, indicating a tighter market presence.

The short-interest ratio stands at 1.0 days based on an average daily trading volume of 520,008 shares, suggesting a relatively stable trading environment for the stock.

Analyst Ratings and Market Outlook

Recent evaluations by financial analysts reveal mixed sentiments regarding VYNE shares. Weiss Ratings maintained a “sell (e+)” rating in a research note issued on January 21. Conversely, Wall Street Zen upgraded VYNE Therapeutics from a “sell” to a “hold” rating on February 2. Currently, three analysts have assigned a Hold rating, while one has given a Sell rating. According to MarketBeat, the stock holds a consensus rating of “Reduce” with an average price target of $4.50.

Institutional Investment Activity

Several institutional investors have made significant moves involving VYNE Therapeutics shares recently. Nantahala Capital Management LLC acquired a new position during the fourth quarter, valued at approximately $580,000. T3 Companies LLC also purchased a new stake valued at about $548,000 during the same period.

Adage Capital Partners GP L.L.C. increased its stake in VYNE Therapeutics by 87.2% in the second quarter, now holding 644,134 shares valued at around $1,063,000. Additionally, Kennedy Capital Management LLC acquired a new position in the second quarter worth approximately $942,000. In total, institutional investors and hedge funds control 83.78% of the company’s stock.

VYNE Therapeutics operates as a clinical-stage biopharmaceutical company, focusing on the discovery and development of small-molecule therapies for various diseases, including vascular, inflammatory, and fibrotic conditions. The company is headquartered in the San Francisco Bay Area and is advancing a pipeline of selective oral inhibitors targeting key pathways associated with chronic tissue damage and immune dysregulation.

The company’s leading program, VTX-002, aims to modulate the colony-stimulating factor-1 receptor (CSF-1R) pathway, pivotal in macrophage proliferation and activation. As VYNE Therapeutics continues to navigate the biopharmaceutical landscape, its recent financial indicators and analyst ratings will be critical in shaping investor sentiment and market performance.